• baseline less than (<) 15 letters of the best-corrected visual acuity expressed
• Proportion of responders at 54 weeks, defined as patients having lost from
• as an ETDRS score; this includes patients with visual acuity gain from baseline.

• Change From Baseline in Visual Acuity [ Time Frame: Baseline, 6 weeks, 12 weeks, 54 weeks ] [ Designated as safety issue: No ]
• Number of Subjects Gaining Vision [ Time Frame: 54 weeks or at early termination ] [ Designated as safety issue: No ]
• Number of Subjects Maintaining Vision [ Time Frame: 54 weeks or at early termination ] [ Designated as safety issue: No ]
• Number of Subjects With Severe Visual Loss [ Time Frame: 54 weeks or at early termination ] [ Designated as safety issue: No ]
• Number of Subjects With a Distance Visual Acuity of > 20/200 at Baseline and Progressing to (<= 20/200) [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]
• Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ 25). [ Time Frame: Baseline, 54 weeks or at early termination ] [ Designated as safety issue: No ]

• Proportion of patients with severe visual loss at 54 weeks
• (loss from baseline of more than 30 letters of visual acuity)
• Proportion of patients maintaining vision at 54 weeks
• (gain from baseline of more than 0 letters of visual acuity)
• Proportion of gaining vision at 54 weeks
• (gain from baseline of more than 15 letters of visual acuity)
• Mean change from baseline in visual acuity at 6, 12 and 54 weeks
• Proportion of patients progressing to a visual acuity of < ou = 20/200
• at 54 weeks of those who had a visual acuity of > 20/200 at baseline
• Changes from baseline in patient reported vision-related functioning
• and quality of life as measured using the NEI-VFQ 25 at 54 weeks.

To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization.

Inclusion Criteria:

• Clinical and angiographic evidence of juxtafoveal or subfoveal choroidal neovascularization secondary to AMD with a total lesion size of less than 2 MPS disc areas
• Best-corrected visual acuity in the study eye greater than 54 letters (ETDRS)
• Women must be using 2 forms of effective contraception
• Adequate hematological, renal and liver functions

Exclusion Criteria:

• Any atrophy or fibrosis; any retinal hemorrhage measuring more than 1 disc area
• Any extrafoveal choroidal neovascularization
• Any intraocular surgery or thermal laser to the study eye within 3 months of enrollment
• Previous or concomitant therapy for AMD including PDT with verteporfin (Visudyne) or subfoveal/non-foveal thermal laser therapy, transpupillary thermotherapy, external beam radiation, submacular surgery.
• Presence of other causes of choroidal neovascularization, including pathological myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis